Oncolytic Immunotherapy

被引：11

作者：

Hennessy, Morgan L. ^{[1
]}

Bommareddy, Praveen K. ^{[2
]}

Boland, Genevieve ^{[1
]}

Kaufman, Howard L. ^{[1
,3
]}

机构：

[1] Massachusetts Gen Hosp, Div Surg Oncol, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA

[2] Rutgers State Univ, Sch Grad Studies, Grad Sch Biomed Sci, 195 Little Albany St, New Brunswick, NJ 08901 USA

[3] Replimune Inc, Woburn, MA 01801 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2019年 / 28卷 / 03期

关键词：

Cancer; Immunogenic cell death; Immunotherapy; Intratumoral; Oncolytic virus; Treatment; PEXA-VEC JX-594; TALIMOGENE LAHERPAREPVEC; LENTIGO MALIGNA; OPEN-LABEL; CANCER; VIRUS; TRIAL; 1ST; IMIQUIMOD; MELANOMA;

D O I：

10.1016/j.soc.2019.02.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Oncolytic viruses are naturally occurring, or genetically engineered viruses that can be administered via intralesional injections or intravenously to induce cell death in tumor cells and activate antitumor immune responses. This review summarizes several oncolytic viruses in preclinical and clinical trials, describes challenges in clinical implementation, and important areas of future investigation.

引用

页码：419 / +

页数：13